[ 18 F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Significance Deoxycytidine kinase (dCK) is required for the activation of multiple nucleoside analog prodrugs used in cancer therapy and is a potential new therapeutic target in hematological malignancies. Here, we identify [ 18 F]Clofarabine; 2-chloro-2′-deoxy-2′-[ 18 F]fluoro-9-β- d -arabinofuranosyl-adenine ([ 18 F]CFA) as a new candidate PET probe for dCK, with superior specificity and biodistribution in humans compared with existing probes. [ 18 F]CFA PET may provide a useful companion biomarker for therapeutic interventions against cancer that include nucleoside analog prodrugs, dCK inhibitors, and immunotherapies.

authors

  • Kim, Woosuk
  • Le, Thuc M
  • Wei, Liu
  • Poddar, Soumya
  • Bazzy, Jimmy
  • Wang, Xuemeng
  • Uong, Nhu T
  • Abt, Evan R
  • Capri, Joseph R
  • Austin, Wayne R
  • Van Valkenburgh, Juno S
  • Steele, Dalton
  • Gipson, Raymond M
  • Slavik, Roger
  • Cabebe, Anthony E
  • Taechariyakul, Thotsophon
  • Yaghoubi, Shahriar S
  • Lee, Jason T
  • Sadeghi Hosseini, Seyed Saman
  • Lavie, Arnon
  • Faull, Kym F
  • Witte, Owen N
  • Donahue, Timothy R
  • Phelps, Michael E
  • Herschman, Harvey R
  • Herrmann, Ken
  • Czernin, Johannes
  • Radu, Caius G

publication date

  • April 12, 2016